Cancer Stem Cell News Volume 2.23 | Jun 12 2013

PUBLICATIONS (Ranked by impact factor of the journal)

Targeting Treatment Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
FKBPL and its peptide derivative, AD-01, have already demonstrated tumor growth inhibition and CD44 dependent anti-angiogenic activity. Investigators explored the ability of AD-01 to target CD44 positive breast cancer stem cells. [Clin Cancer Res] Abstract

miR-27a Regulates Endothelial Differentiation of Breast Cancer Stem Like Cells
Researchers showed that vascular endothelial growth factor induced the expression of endothelial markers in breast cancer stem like cells. [Oncogene] Abstract

Downregulation of miR-140 Promotes Cancer Stem Cell Formation in Basal-Like Early Stage Breast Cancer
Investigators found that microRNA (miR)-140 has a critical role in regulating stem cell signaling in normal breast epithelium and in ductal carcinoma in situ. [Oncogene] Abstract

MicroRNA-128 Coordinately Targets Polycomb Repressor Complexes in Glioma Stem Cells
Researchers used a set of glioblastoma patient samples, glioma stem cells, and neural stem cells from a mouse model of glioblastoma. They characterized gene/protein expression and cellular phenotypes by quantitative PCR/Western blotting and clonogenic, cell-cycle, and DNA damage assays. They performed overexpression/knockdown studies by lentiviral infection and microRNA/small interfering RNA oligonucleotide transfection. [Neuro Oncol] Abstract

Brain Tumor Stem Cell Multipotency Correlates with Nanog Expression and Extent of Passaging in Human Glioblastoma Xenografts
The authors present a study detailing changes in brain tumor stem cell multipotency, invasive migration, and proliferation after serial passaging of human glioblastoma multiforme xenografts. [Oncotarget] Full Article

Non-Hematopoietic Cells Represent a More Rational Target of In Vivo Hedgehog Signaling Affecting Normal or Acute Myeloid Leukemic Progenitors
Recent work has shown that leukemic stem cell self-renewal in chronic myeloid leukemia is dependent on cell-intrinsic hedgehog (Hh) signaling, and early clinical trials suggest targeting this pathway is also therapeutic in acute myeloid leukemia (AML) patients. Researchers aimed to better understand Hh signaling in normal hematopoiesis and AML by molecularly and functionally analyzing over 200 primary human AML patient samples compared to non-leukemic controls. [Exp Hematol] Abstract

Establishment of a Human Colorectal Cancer Cell Line P6C with Stem Cell Properties and Resistance to Chemotherapeutic Drugs
Scientists established a CD44⁺ colorectal cancer stem cell line with particular emphasis on its self-renewal capacity, enhanced tumor initiation and drug resistance. [Acta Pharmacol Sin] Full Article

Assessment of Genetic Markers and Glioblastoma Stem-Like Cells in Activation of Dendritic Cells
The authors aimed to determine the role of tailored cellular therapy for glioblastoma (GBM) with a poor prognosis and to compare the activity of dendritic cells that have encountered GBM cells. Detecting the correlations between methylation and expression of MGMT and PTEN genes and GBM cancer stem cells markers after co-cultures with a mononuclear cell cocktail were also aims for this study. [Hum Cell] Abstract

HER2 and Breast Cancer Stem Cells: More than Meets the Eye
The development of HER2 targeting agents has dramatically altered the natural history of HER2-positive breast cancer and is often cited as a prime example of the effectiveness of molecularly targeted therapy. Emerging data suggest that the remarkable clinical efficacy of these agents may be related to their ability to target the breast cancer stem cell (CSC) population. In addition to having significant implications for breast cancer therapy, these studies suggest the need to reevaluate the role of HER2 in regulating CSCs in other tumor types. [Cancer Res] Abstract

HIF Expression and the Role of Hypoxic Microenvironments within Primary Tumors as Protective Sites Driving Cancer Stem Cell Renewal and Metastatic Progression
This article reviews the molecular mechanisms underlying tumor hypoxia and their pro-tumor contributions such as immune suppression, development of nascent and more permeable tumor vasculature, selective cancer stem cell renewal, accumulation, mobilization and promotion of epithelial to mesenchymal transition leading to tumor cell metastasis. [Carcinogenesis] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Stemline Therapeutics’ SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc. announced that SL-401 has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of BPDCN, a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 is a novel targeted therapy directed to the interleukin-3 receptor present on tumor bulk and cancer stem cells of multiple hematologic cancer indications. [Stemline Therapeutics, Inc.] Press Release

ImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial following Interim Analysis
ImmunoCellular Therapeutics, Ltd. announced that the Data Monitoring Committee has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion. The ICT-107 phase II trial is a randomized, placebo-controlled, double-blind study of ICT-107, a 6-antigen dendritic cell vaccine targeting glioblastoma tumor and cancer stem cell antigens, as a potential treatment for patients with newly diagnosed glioblastoma. [ImmunoCellular Therapeutics, Ltd.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

NEW Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Fellow – Cancer Biology and Stem Cell (University of Texas Health Science Center at Houston)

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati College of Medicine)

Postdoctoral Associate – Salivary Gland Cancers (Yale School of Medicine)

Postdoctoral Fellow – Stem Cells and Cancer (Tsinghua University)

Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine)

PhD Studentship Opportunity – Tumor-Initiating Melanoma Cells (University of East Anglia)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.